8-99442535-CCT-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_017890.5(VPS13B):βc.3348_3349delβ(p.Cys1117PhefsTer8) variant causes a frameshift change. The variant allele was found at a frequency of 0.000111 in 1,613,806 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00026 ( 0 hom., cov: 32)
Exomes π: 0.000096 ( 0 hom. )
Consequence
VPS13B
NM_017890.5 frameshift
NM_017890.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.69
Genes affected
VPS13B (HGNC:2183): (vacuolar protein sorting 13 homolog B) This gene encodes a potential transmembrane protein that may function in vesicle-mediated transport and sorting of proteins within the cell. This protein may play a role in the development and the function of the eye, hematological system, and central nervous system. Mutations in this gene have been associated with Cohen syndrome. Multiple splice variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 8-99442535-CCT-C is Pathogenic according to our data. Variant chr8-99442535-CCT-C is described in ClinVar as [Pathogenic]. Clinvar id is 2818.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-99442535-CCT-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
VPS13B | NM_017890.5 | c.3348_3349del | p.Cys1117PhefsTer8 | frameshift_variant | 23/62 | ENST00000358544.7 | |
VPS13B | NM_152564.5 | c.3348_3349del | p.Cys1117PhefsTer8 | frameshift_variant | 23/62 | ENST00000357162.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
VPS13B | ENST00000357162.7 | c.3348_3349del | p.Cys1117PhefsTer8 | frameshift_variant | 23/62 | 1 | NM_152564.5 | P1 | |
VPS13B | ENST00000358544.7 | c.3348_3349del | p.Cys1117PhefsTer8 | frameshift_variant | 23/62 | 1 | NM_017890.5 |
Frequencies
GnomAD3 genomes AF: 0.000256 AC: 39AN: 152098Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
39
AN:
152098
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000227 AC: 57AN: 251260Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135774
GnomAD3 exomes
AF:
AC:
57
AN:
251260
Hom.:
AF XY:
AC XY:
25
AN XY:
135774
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000958 AC: 140AN: 1461708Hom.: 0 AF XY: 0.0000839 AC XY: 61AN XY: 727166
GnomAD4 exome
AF:
AC:
140
AN:
1461708
Hom.:
AF XY:
AC XY:
61
AN XY:
727166
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000256 AC: 39AN: 152098Hom.: 0 Cov.: 32 AF XY: 0.000390 AC XY: 29AN XY: 74298
GnomAD4 genome
AF:
AC:
39
AN:
152098
Hom.:
Cov.:
32
AF XY:
AC XY:
29
AN XY:
74298
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cohen syndrome Pathogenic:6Other:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 09, 2020 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Apr 26, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 09, 2019 | NM_017890.4(VPS13B):c.3348_3349delCT(C1117Ffs*8) is classified as pathogenic in the context of Cohen syndrome. Sources cited for classification include the following: PMID 12730828 and 15141358. Classification of NM_017890.4(VPS13B):c.3348_3349delCT(C1117Ffs*8) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 17, 2021 | Variant summary: VPS13B c.3348_3349delCT (p.Cys1117PhefsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 0.00023 in 251260 control chromosomes. c.3348_3349delCT has been reported in the literature as a recurrent Finnish founder variant in multiple individuals affected with Cohen Syndrome (Kolehmainen_2003) and has been subsequently cited by others in the field (example, Enomoto_2020, Kondo_2005, Lou_2020, Nasser_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2023 | This sequence change creates a premature translational stop signal (p.Cys1117Phefs*8) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 2818). This premature translational stop signal has been observed in individual(s) with Cohen syndrome (PMID: 12730828, 15141358). This variant is present in population databases (rs774683328, gnomAD 0.3%). - |
not provided Pathogenic:1Other:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2019 | - - |
not provided, no classification provided | literature only | SNPedia | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at